ATE260119T1 - Zusammensetzungen von adenosin a1 agonisten und cox2-hemmern - Google Patents

Zusammensetzungen von adenosin a1 agonisten und cox2-hemmern

Info

Publication number
ATE260119T1
ATE260119T1 AT00985627T AT00985627T ATE260119T1 AT E260119 T1 ATE260119 T1 AT E260119T1 AT 00985627 T AT00985627 T AT 00985627T AT 00985627 T AT00985627 T AT 00985627T AT E260119 T1 ATE260119 T1 AT E260119T1
Authority
AT
Austria
Prior art keywords
adenosine
agonists
compositions
cox2 inhibitors
solvate
Prior art date
Application number
AT00985627T
Other languages
English (en)
Inventor
Charanjit Bountra
Stevenage
Nicholas Maughan Clayton
Alan Naylor
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE260119T1 publication Critical patent/ATE260119T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00985627T 1999-12-20 2000-12-19 Zusammensetzungen von adenosin a1 agonisten und cox2-hemmern ATE260119T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9930075.8A GB9930075D0 (en) 1999-12-20 1999-12-20 Medicaments
PCT/GB2000/004883 WO2001045683A2 (en) 1999-12-20 2000-12-19 Formulations of adenosine a1 agonists

Publications (1)

Publication Number Publication Date
ATE260119T1 true ATE260119T1 (de) 2004-03-15

Family

ID=10866659

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00985627T ATE260119T1 (de) 1999-12-20 2000-12-19 Zusammensetzungen von adenosin a1 agonisten und cox2-hemmern

Country Status (8)

Country Link
US (1) US20030004128A1 (de)
EP (1) EP1239879B1 (de)
JP (1) JP2003519104A (de)
AT (1) ATE260119T1 (de)
AU (1) AU2203401A (de)
DE (1) DE60008590T2 (de)
GB (1) GB9930075D0 (de)
WO (1) WO2001045683A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105144A1 (en) 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
GB0115182D0 (en) * 2001-06-20 2001-08-15 Glaxo Group Ltd Medicaments
GB0115178D0 (en) * 2001-06-20 2001-08-15 Glaxo Group Ltd Compounds
EP1513858A2 (de) * 2002-06-17 2005-03-16 Glaxo Group Limited Verfahren zur herstellung von heterocyclyl-substituierten adenosinderivaten
EP1714240A1 (de) 2004-02-03 2006-10-25 Swiss Reinsurance Company System und verfahren zur automatisierten risikoanalyse und/oder optimierung der betriebsdauer von technischer anlagen
MX2007006091A (es) * 2007-05-21 2009-02-25 World Trade Imp Export Wtie Ag Composicion farmaceutica que comprende la combinacion de un agente antiinflamatorio no esteroideo y un agente anticonvulsionante.
CN104983714A (zh) * 2015-08-06 2015-10-21 苏州二叶制药有限公司 一种塞来昔布胶囊及其制备方法
CN105125520A (zh) * 2015-09-29 2015-12-09 深圳瑞多力泰医药科技实业有限公司 一种塞来昔布制剂及其制备方法和控制方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20000270A1 (es) * 1998-02-14 2000-05-20 Glaxo Group Ltd Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol

Also Published As

Publication number Publication date
DE60008590D1 (de) 2004-04-01
WO2001045683A3 (en) 2002-03-14
GB9930075D0 (en) 2000-02-09
EP1239879A2 (de) 2002-09-18
US20030004128A1 (en) 2003-01-02
WO2001045683A2 (en) 2001-06-28
AU2203401A (en) 2001-07-03
JP2003519104A (ja) 2003-06-17
DE60008590T2 (de) 2004-08-05
EP1239879B1 (de) 2004-02-25

Similar Documents

Publication Publication Date Title
PL356252A1 (en) Synergistic combination of pde inhibitors and beta 2 adrenoceptor agonist
CR6306A (es) 1,2,3,4-tetrahidroquinlinas 2-sustituidas 4-amino sustituidas
EA200401471A1 (ru) Применение ингибиторов сетр и возможных ингибиторов hmg coa и/или антигипертензивных агентов
HUP0203590A2 (hu) Gyógyszerkészítmény a csonttömeg csökkenésével járó betegségek kezelésére
HUP0104696A2 (hu) 5HT1 receptor agonistákat és metoklopramidot tartalmazó gyógyszerkészítmény migrén kezelésére
DK1545537T3 (da) Alfa-7-nikotinreceptoragonister og statiner i kombination
BR0015821A (pt) Derivados de pirimidina
ATE316954T1 (de) N-biphenylmethylaminocycloalkancarboxamid- derivative
EE05054B1 (et) 5-HT4 agonisti v?i antagonisti peroraalne ravimkoostis ja selle kasutamine meditsiinis
NO20054216L (no) Anvendelse av dipyridamol i kombinasjon med acetylsalisylsyre og en angiotensin II antagonist for forhindring av slag
DK1303278T3 (da) Kombination af et transdermalt terapeutisk system og et oralt og/eller parenteralt præparat indeholdende dopaminagonister til behandling af dopaminerge sygdomme
ATE260119T1 (de) Zusammensetzungen von adenosin a1 agonisten und cox2-hemmern
BR9809848A (pt) Composição
WO2001045684A3 (en) Formulations of adenosine a1 agonists
BR0206819A (pt) Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca
ATE277639T1 (de) Zusammensetzungen von adenosin a1 agonisten und 5ht3 agonisten
BR0209155A (pt) Tablete farmacêutico tendo um teor de api elevado
DE60008589D1 (de) Zusammensetzungen von adenosin a1 agonisten mit 5ht1 agonisten
AR037496A1 (es) Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables
HUP0001888A2 (hu) 5HT1 Agonistát és COX-2 inhibitort vagy NSAID-t tartalmazó gyógyszerészeti összetétel migrén kezelésére
WO2001045714A3 (en) Formulations of adenosine a1 agonists
EP1051995A3 (de) 5HT1-Rezeptor-Agonisten und COX-2 Inhibitoren zur Behandlung von Migräne
AR045074A1 (es) Uso de cd164 soluble en desordenes inflamatorios y autoinmunes
BG108144A (en) New use
WO2001045686A3 (en) Formulations of adenosine a1 agonists

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties